



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Darrell R. Anderson, et al.

Group Art Unit: 1644

Application No. 09/758,173

Filed: January 12, 2001

Title: HUMAN B7.1 SPECIFIC PRIMATIZED ANTIBODIES AND TRANSFECTOMAS  
EXPRESSING SAID ANTIBODIES

\* \* \* \* \*

REQUEST TO USE COMPUTER READABLE  
SEQUENCE LISTING FORM FROM PARENT APPLICATION

RECEIVED

Hon. Commissioner of Patents  
2022 South Clark Place  
Crystal Plaza Two, Lobby, Room 1B03, Box Sequence  
Arlington, VA 22202  
ATTN: CUSTOMER WINDOW

APR 15 2002

TECH CENTER 1600/2900

Sir:

Applicants advise that the computer readable form in the above-identified application is identical with that filed in U.S. Serial No. 09/383,916, filed August 26, 1999, which is a divisional of U.S. Serial No. 08/487,550, filed June 7, 1995.

Accordingly, in accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed in the parent application, Serial No. 09/383,916, as the computer readable form for the instant application. It is understood that the U.S. Patent & Trademark Office will make the necessary change in application and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing, as filed in the parent application, is to be incorporated into the present specification.

Respectfully submitted,

Pillsbury Winthrop LLP

Date:

4/12/02

By:

Robin L. Teskin

Registration No. 35,030

1600 Tysons Boulevard  
McLean, VA 22102  
(703) 905-2200 Telephone  
(703) 905-2500 Facsimile

Group Art Unit 1644  
 Examiner: Gambel  
 Atty. Dkt. P 276603

1995-30-0233C2

Appln. Title: HUMAN B7.1 SPECIFIC PRIMATIZED  
 ANTIBODIES AND TRANSFECTOMAS  
 EXPRESSING SAID ANTIBODIES

RECEIVED

Inventor(s): ANDERSON et al.

Appln. No.: 09 758,173

Series Code ↑

Serial No. ↑

Filed: January 12, 2001

Hon. Commissioner of Patents  
 Washington, D.C. 20231

Sir:

## REPLY/AMENDMENT/LETTER

Date: April 12, 2002 APR 15 2002

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of some data and a signature thereto.

## FEE REQUIREMENTS FOR CLAIMS AS AMENDED

## 1. Small Entity claim

- A. ☒ NOT made  
 B. ☐ Withdrawn  
 C. ☐ made herewith  
 D. ☐ made previously
- For B & C  
 See Required  
 Separate Paper  
 (Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	16	**minus 20	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	1	***minus 3	0	x \$84/\$42 =	+ \$0 102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)..... add			+ \$280/\$140 =	+ \$0	104/204
5. Original due Date: April 12, 2002 <input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached					
(1 mo) \$110/\$55 =			115/215		
(2 mos) \$400/\$200 =			116/216		
(3 mos) \$920/\$460 =			117/217		
(Usable only for ≤ 2mo.OA --- 4 mos) \$1,440/\$720=			118/218		
(Usable only for 30 day/1mo.OA --- 5 mos) \$1,960/\$980=			128/228		
7. Enter any previous extension fee paid since above original due date and subtract			- \$0		
8. Extension Fee Attached			+ \$0		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee .....			+ \$110/\$55 + \$0 148/248		
10. If IDS attached requires Official Fee under Rule 97 (c), ..... add			+ \$180 + \$0 126		
or if Rule 97(d) Request ..... add			+ \$180 + \$0 126		
11. After-Final Request Fee per rules 129(a) and 17(r) .....			+ \$740/370 + \$0 146/246		
12. No. of additional inventions for examination per Rule 129(b).....			x \$740/370 ea + \$0 149/249		
13. Request for Continued Examination (RCE) .....			+ \$740/370 + \$0 1179/1279		
14. Request to Use Computer Readable Sequence Listing Form From Parent Application			+ \$0		
15. TOTAL FEE ENCLOSED =			\$0		

16. If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. \*\*If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. \*\*\*If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 037003 276603

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP  
 Intellectual Property Group

By Atty: Robin L. Teskin

Reg. No. 35,030

1600 Tysons Boulevard

McLean, VA 22102

Tel: (703) 905-2000

Sig:

Fax: (703) 905-2500

Tel: (703) 905-2200

Atty/Sec: RLT/AF

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments